ALNY Stock Recent News

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants David Lebowitz – Citi Paul Matteis – Stifel Maury Raycroft – Jefferies Gary Nachman – Raymond James Tazeen Ahmad – BofA Securities Ritu Baral – TD Cowen Jessica Fye – JPMorgan Kostas Biliouris – BMO Capital Markets Ellie Merle – UBS Gena Wang – Barclays Mike Ulz – Morgan Stanley Whitney Ijem – CG Operator Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Quarter One 2024 Conference Call.

Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.40 per share a year ago.

Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2024 results as well as expectations for the future via conference call on Thursday, May 2, 2024 at 8:30 am ET. To access the call, please r.

Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, at the American College of Cardiology (ACC) Scientific Session on Sunday, April 7, 2024 at 7:00 pm ET. The event will include pr.

Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.

Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.